1. A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: A report from the Children's Oncology Group. Issue 10 (29th June 2014) Authors: Horton, Terzah M.; Perentesis, John P.; Gamis, Alan S.; Alonzo, Todd A.; Gerbing, Robert B.; Ballard, Jennifer; Adlard, Kathleen; Howard, Dianna S.; Smith, Franklin O.; Jenkins, Gaye; Kelder, Angelé; Schuurhuis, Gerrit J.; Moscow, Jeffrey A. Journal: Pediatric blood & cancer Issue: Volume 61:Issue 10(2014:Oct.) Page Start: 1754 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy. Issue 1 (December 2016) Authors: Niewerth, Denise; Kaspers, Gertjan; Jansen, Gerrit; van Meerloo, Johan; Zweegman, Sonja; Jenkins, Gaye; Whitlock, James; Hunger, Stephen; Lu, Xiaomin; Alonzo, Todd; van de Ven, Peter; Horton, Terzah; Cloos, Jacqueline Journal: Journal of hematology & oncology Issue: Volume 9:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗